Neumora Therapeutics has reported a cash position of $182.5 million in cash, cash equivalents and marketable securities as of 31 December 2025, expected to support operations into the third quarter of 2027. The company's net loss for 2025 was comparable to 2024. Neumora announced positive Phase Ib results for NMRA-511 in Alzheimer's disease agitation and has fully enrolled KOASTAL-2 and KOASTAL-3 studies for navacaprant, with data expected in the second quarter of 2026. The company also reported promising data for NMRA-898 in schizophrenia and class-leading weight loss results for NMRA-215. However, unexpected adverse findings in a rat toxicology study for NMRA-215 have delayed clinical trials until the first quarter of 2027.

Neumora Therapeutics to participate in Guggenheim Emerging Outlook: Biotech Summit 2026. By GlobeNewswire February 4, 2026 WATERTOWN, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) - Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 4:00 p.m. ET in New York, NY. A live webcast of the fireside chat will be available on the events and presentations section of the Company's website at www.neumoratx.com. A replay of the webcast will be available following the completion of the event and will be archived for up to 30 days. About Neumora Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our therapeutic pipeline currently consists of seven neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Our work is supported by an integrated suite of translational, clinical and computational tools to generate insights that can enable precision medicine approaches. Neumora's mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases. Neumora Contact: Helen Rubinstein 617-402-5700 [email protected]

Dr. Dam joins Brenig from Neumora Therapeutics, where she was Vice President of Clinical Development, leading strategy and execution across neuropsychiatry and neurodegeneration programs.